Is Becton Dickinson (BDX) Still A Bargain After A 24% Gain?
Becton Dickinson has delivered a 24.5% gain over the past year, yet current valuation checks suggest the stock may still sit below an intrinsic value estimate based on Discounted Cash Flow, creating a gap between recent share performance and what the models say the business could be worth. For investors, the question is whether that combination of a solid 12 month return and an intrinsic value estimate pointing to undervaluation offers enough margin of safety at recent prices.
- The share price has climbed 24.5% over the past year, which signals that sentiment toward Becton Dickinson has improved despite weaker multi year returns.
- Participation in efforts such as the Medicinal Hazard Data Standardization Consortium and ongoing work in advanced tissue regeneration can support long term cash flow expectations, while execution risk around clinical outcomes and product adoption may limit how quickly those benefits show up in valuation.
- A value score of 4 out of 6 gives a mixed picture rather than a clear bargain or clear overvaluation, even though both the Discounted Cash Flow intrinsic value estimate and earnings multiples currently lean toward Becton Dickinson looking undervalued.
The issue now is whether that combination of recent share gains and an intrinsic value estimate with a 23.7% discount leaves enough upside to justify fresh capital at current levels.
Spot 49 high quality undervalued stocks that, like Becton Dickinson, combine signs of undervaluation on cash flow models with improving sentiment in the share price.Does Becton Dickinson Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) method used here projects what Becton Dickinson could return to shareholders in future cash terms and then discounts that back to today. On this model, the latest twelve-month free cash flow is about $2.6b, with the forecast path assuming growing cash flows rather than a sharp ramp up or contraction. Feeding that stream into a 2 Stage Free Cash Flow to Equity model gives an estimated intrinsic value of about $236 per share.
Compared with the current market price, that DCF output implies the stock trades at roughly a 23.7% discount, which is a meaningful gap for a large medical equipment business. The recent commitment to the Medicinal Hazard Data Standardization Consortium helps explain why investors may be willing to pay more for potential future cash generation, because it links Becton Dickinson to long-running projects in safety and standard setting that can support long-term demand, even if the share price has not fully closed the discount yet.
On this DCF view, Becton Dickinson appears undervalued relative to the cash flows the model is pricing in.
Our Discounted Cash Flow (DCF) analysis suggests Becton Dickinson is undervalued by 23.7%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.
Does Becton Dickinson Look Undervalued on Earnings?
P/E works well for Becton Dickinson because earnings remain a core focus for how investors judge large medical equipment groups. On this measure, the stock trades on a P/E of about 29.7x, which is slightly below both the Medical Equipment industry average of roughly 26.3x and a peer group level of about 30.4x.
The tailored fair P/E ratio for Becton Dickinson is estimated at about 40.1x. That sits well above the current multiple and indicates that, given the company’s size, sector, margin profile and risk mix, the shares reflect less earnings value than this model would suggest. For readers, the key point is that the market is not attaching a premium P/E to the stock even though the fair ratio indicates room for a higher earnings multiple.
On the P/E yardstick, Becton Dickinson appears undervalued relative to what this fair multiple framework indicates investors might be willing to pay for its earnings.
See what the numbers say about this price — find out in our valuation breakdown.
The Becton Dickinson Narrative: What Would Justify Today's Price?
Simply Wall St Narratives take the valuation puzzle around Becton Dickinson and spell out which specific paths for growth, margins and earnings would need to play out for the stock to be worth meaningfully more or less than today’s price on the Community page. Rather than stopping at a single ratio or model output, they unpack the future that number quietly assumes so you can watch how Becton Dickinson’s actual progress lines up with those expectations.
Community views on Becton Dickinson sit far apart, with one camp focused on margin upside and another worried about 2027 pressure and inflation.
Bull case: 8% undervalued
"The successful execution and ramping benefits of the BD Excellence operating system is yielding sustained reductions in manufacturing waste and improved operational throughput…"
Read the full Bull Case to see why Becton Dickinson could be undervalued
Bear case: 6% overvalued
"Heightened global healthcare cost-containment efforts and increasing preference for low-cost suppliers threaten Becton Dickinson's ability to maintain pricing power and margin stability…"
Read the full Bear Case to see why Becton Dickinson could be overvalued
Do you think there's more to the story for Becton Dickinson? Head over to our Community to see what others are saying!
The Bottom Line
Becton Dickinson screens as undervalued on both Discounted Cash Flow (DCF) and earnings multiple checks, which is a rare alignment. The intrinsic value estimate and the fair P/E framework both point to a stock that the models suggest is priced below what its cash flows and earnings profile imply. The mixed overall value score tempers that message and flags that other cross checks are less emphatic. The key question from here is whether Becton Dickinson can convert its pipeline, cost work and consortium initiatives into durable margins that justify a higher multiple, rather than the current discount proving to be a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com